Novo Nordisk reveals obesity drug with up to 22 percent weight lossJanuary 24, 2025 Novo Nordisk’s amycretin shows up to 22% weight loss in trials, boosting its stock by 6.87% as the drug exhibits safety and potential as a next-gen obesity treatment.
